ClinicalTrials.gg
Not yet recruitingNCT07908342Updated Nov 2, 2026

Application of Perinatal Derivatives in Total Knee Arthroplasty

An interventional study of Intraoperative application of CTM Flow and CTM Thick and Total knee arthroplasty (TKA) in Total Knee Arthroplasty and Knee Osteoarthristis, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute). Not yet recruiting. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Not applicable, Interventional, and Treatment

Updated Nov 2, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

This pilot study investigators whether the use of perinatal derivatives during knee replacement, in the form of an injection around the joint and patch over the knee joint incision, improves patient outcomes (including survey-based measures, functional outcomes and wound healing). Perinatal derivatives are materials derived from donor placental tissue, including amnion, chorion and umbilical cord. The perinatal derivatives used in this study do not contain living cells.

Forty-eight patients aged 40 to 75 years undergoing knee replacement will be enrolled in this study and randomized to either receive or not receive perinatal derivatives during knee replacement. Participants will follow-up in clinic at Week 2, Week 6 and Month 3 after surgery. An additional remote visit will be conducted at Year 1 after surgery. Outcomes that will be assessed include the visual analogue scale (VAS) for pain, Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS JR), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Oxford Knee Score (OKS) and wound healing (using a standard wound healing assessment).

02

Conditions studied

  • Total Knee Arthroplasty
  • Knee Osteoarthristis

Keywords

  • Total Knee Arthroplasty
  • TKA
  • Perinatal Derivative
  • CTM
  • PnD
03

In context

Lead sponsor

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) is the lead sponsor of 49 studies on the registry; 20 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 40 and 75 years of age
  • Patients who are medically cleared and scheduled for unilateral primary total knee replacement
  • No focal neurologic deficit of the surgical lower extremity
  • Cognitively intact with the ability to sign

Exclusion criteria

Exclusion Criteria:

  • Chronic pain syndromes such as fibromyalgia or complex regional pain syndrome
  • History of long term use of daily opioids (>1 months) with oral morphine equivalent (OME) >5mg/day.
  • (BMI) > 40 kg/m2
  • Allergies to medications used in this study such as: fentanyl, hydromorphone, ketorolac, ibuprofen, acetaminophen, local anesthetics, oxycodone, OxyContin, tramadol, ondansetron, droperidol, or dexamethasone, celecoxib
  • Major systemic medical problems such as:
  • Severe renal disorder defined as (GFR) \<50 units/m2
  • Cardiovascular disorders defined as congestive heart failure (CHF) (NYHA) class III-IV
  • Severe hepatic disorder defined as current or past diagnosis of acute/subacute necrosis liver, acute hepatic failure, chronic liver disease, cirrhosis (primary biliary cirrhosis), fatty liver, chronic hepatitis/toxic hepatitis, liver abscess, hepatic coma, hepatorenal syndrome, other disorders of liver.
  • Impaired cognitive function or inability to understand the study protocol
  • to a regional anesthesia technique (e.g., preexisting neuropathy in the operative extremity, coagulopathy [ \< 100,000, (INR) >1.5], refusal, etc.).
  • Previous contralateral knee replacement managed with regional or periarticular injection
  • Unable to follow-up at the one year interval at Allegheny Health Network
  • Pregnancy or breast feeding (women of , must have a negative pregnancy test)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Active comparator
    Total Knee Replacement

    Patients will undergo standard of care total knee replacement.

    Procedure: Total knee arthroplasty (TKA)

  • Experimental
    Total Knee Replacement with CTM

    Patients will be treated with a perinatal derivative injection and patch during standard of care total knee replacement.

    Biological: Intraoperative application of CTM Flow and CTM Thick · Procedure: Total knee arthroplasty (TKA)

Interventions

  • BiologicalIntraoperative application of CTM Flow and CTM Thick

    Perinatal derivative connective tissue allograft

    Also known as: CTM Flow, CTM Thick

  • ProcedureTotal knee arthroplasty (TKA)

    Standard of care total knee arthroplasty (TKA)

    Also known as: Total knee replacement

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at Month 3

    Time frame: Baseline and Month 3

Secondary outcomes

  1. Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at Week 2, Week 6 and Year 1

    Time frame: Baseline, Week 2, Week 6 and Year 1

  2. Change from Baseline in Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS JR) Score at Week 2, Week 6, Month 3 and Year 1

    Time frame: Baseline, Week 2, Week 6, Month 3 and Year 1

  3. Change from Baseline in Visual Analog Scale (VAS) Score for Pain at Week 2, Week 6, Month 3 and Year 1

    Time frame: Baseline, Week 2, Week 6, Month 3 and Year 1

  4. Change from Baseline in Oxford Knee Score (OKS) at Week 6, Month 3 and Year 1

    Time frame: Baseline, Week 6, Month 3 and Year 1

  5. Change from Baseline in Range of Motion

    Time frame: Baseline, Week 2, Week 6 and Month 3

  6. SMARrt Wound Tool

    Time frame: Week 2, Week 6 and Month 3

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07908342
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Collaborators
CTM Biomedical
Responsible party
Brian Moore, MD (Physician, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)) — Principal investigator
First posted
Nov 2, 2026
Start date
Dec 2026 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Clinical Research Coordinator
Contact
mary.fetter@ahn.org
412-359-8292
Brian F. Moore, M.D.
principal investigator · Department of Orthopaedics, Allegheny Health Network

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion